Yalcin Elvan, Balci Ozlem
World Eye Hospital, Department of Pediatric Ophthalmology, Istanbul, Turkey.
Clin Ophthalmol. 2014;8:49-53. doi: 10.2147/OPTH.S48300. Epub 2013 Dec 12.
The purpose of this study was to evaluate the efficacy of neural vision therapy, also termed perceptual vision therapy, in enhancing best corrected visual acuity (BCVA) and contrast sensitivity function in amblyopic patients.
This prospective study enrolled 99 subjects previously diagnosed with unilateral hypermetropic amblyopia aged 9-50 years. The subjects were divided into two groups, with 53 subjects (53 eyes) in the perceptual vision therapy group and 46 subjects (46 eyes) in the control group. Because the nature of the treatment demands hard work and strict compliance, we enrolled the minimal number of subjects required to achieve statistically significant results. Informed consent was obtained from all subjects. Study phases included a baseline screening, a series of 45 training sessions with perceptual vision therapy, and an end-of-treatment examination. BCVA and contrast sensitivity function at 1.5, 3, 6, 12, and 18 cycles per degree spatial frequencies were obtained for statistical analysis in both groups. All subjects had follow-up examinations within 4-8 months. With the exception of one subject from the study group and two subjects from the control group, all subjects had occlusion during childhood. The study was not masked.
The results for the study group demonstrated a mean improvement of 2.6 logarithm of the minimum angle of resolution (logMAR) lines in visual acuity (from 0.42 to 0.16 logMAR). Contrast sensitivity function improved at 1.5, 3, 6, 12, and 18 cycles per degree spatial frequencies. The control group did not show any significant change in visual acuity or contrast sensitivity function. None of the treated eyes showed a drop in visual acuity. Manifest refractions remained unchanged during the study.
The results of our study demonstrate the efficacy of perceptual vision therapy in improving visual acuity. The 2.6 logMAR lines improvement in visual acuity is encouraging, and is consistent with the results of previous studies. However, long-term follow-up and further studies are needed.
本研究旨在评估神经视觉疗法（也称为感知视觉疗法）对提高弱视患者最佳矫正视力（BCVA）和对比敏感度功能的疗效。
这项前瞻性研究纳入了99名年龄在9至50岁之间、先前被诊断为单侧远视性弱视的受试者。受试者被分为两组，感知视觉治疗组有53名受试者（53只眼），对照组有46名受试者（46只眼）。由于治疗的性质需要努力和严格遵守，我们纳入了获得统计学显著结果所需的最少受试者数量。所有受试者均获得了知情同意。研究阶段包括基线筛查、一系列45次感知视觉治疗训练课程以及治疗结束时的检查。两组均获取了1.5、3、6、12和18周/度空间频率下的最佳矫正视力和对比敏感度功能数据用于统计分析。所有受试者在4至8个月内进行了随访检查。除研究组的一名受试者和对照组的两名受试者外，所有受试者在儿童期均有过遮盖史。本研究未设盲。
研究组结果显示，视力平均提高了2.6个最小分辨角对数（logMAR）行（从0.42 logMAR提高到0.16 logMAR）。在1.5、3、6、12和18周/度空间频率下，对比敏感度功能有所改善。对照组的视力或对比敏感度功能未显示出任何显著变化。所有接受治疗的眼睛视力均未下降。在研究期间，显验光屈光度保持不变。
我们的研究结果证明了感知视觉疗法在提高视力方面的疗效。视力提高2.6个logMAR行令人鼓舞，且与先前研究结果一致。然而，仍需要长期随访和进一步研究。
